Alto Neuroscience (ANRO): Evaluating Valuation After FDA Fast Track Milestone for Lead Schizophrenia Candidate

Alto Neuroscience (ANRO) drew investor focus this week after announcing the FDA’s Fast Track designation for its lead candidate, ALTO-101, targeting cognitive impairment in schizophrenia. This ...
Stocktwits on MSN

Alto Neuroscience Stock Soars After FDA Grants Fast Track Designation To Schizophrenia Drug

Shares of Alto Neuroscience (ANRO) soared 54% on Friday afternoon after the company announced that the U.S. Food and Drug ...
The Bakersfield Californian

Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that ...
Nature

Motac Neuroscience Ltd.

Article ‘Count’ and ‘Share’ for Motac Neuroscience Ltd. based on listed parameters only. The articles listed below published by authors from Motac Neuroscience Ltd., organized by journal and article, ...

Alto Neuroscience stock soars after FDA grants Fast Track designation

Investing.com -- Alto Neuroscience Inc (NYSE:ANRO) stock surged 32.3% Friday after the company announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its drug ...